Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C22H27N3O4S |
Molar mass | 429.54 g·mol−1 |
3D model (JSmol) | |
| |
|
BC-LI-0186 is a compound that acts as an inhibitor of the GTPase enzyme leucyl-tRNA synthetase (LRS). This enzyme acts as part of the mTOR complex and acts as a leucine sensor which stimulates mTORC1 in the presence of leucine. BC-LI-0186 blocks the docking site for mTORC1 and thereby prevents the mTOR activation and increased protein synthesis which is usually triggered by branched-chain amino acids such as leucine, yet without inhibiting the separate catalytic activity of LRS.[1] This may have potential applications in the treatment of cancer,[2] and BC-LI-0186 has also been shown to promote muscle regeneration after injury.[3]
References
- ↑ Kim JH, Lee C, Lee M, Wang H, Kim K, Park SJ, et al. (September 2017). "Control of leucine-dependent mTORC1 pathway through chemical intervention of leucyl-tRNA synthetase and RagD interaction". Nature Communications. 8 (1): 732. Bibcode:2017NatCo...8..732K. doi:10.1038/s41467-017-00785-0. PMC 5622079. PMID 28963468.
- ↑ Kim EY, Lee JG, Lee JM, Kim A, Yoo HC, Kim K, et al. (2019). "Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer". Therapeutic Advances in Medical Oncology. 11: 1758835919846798. doi:10.1177/1758835919846798. PMC 6535710. PMID 31205503.
- ↑ Son K, You JS, Yoon MS, Dai C, Kim JH, Khanna N, et al. (April 2019). "Nontranslational function of leucyl-tRNA synthetase regulates myogenic differentiation and skeletal muscle regeneration". The Journal of Clinical Investigation. 129 (5): 2088–2093. doi:10.1172/JCI122560. PMC 6486340. PMID 30985292.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.